erythromycin and carbamazepine

Erythromycin is a potent inhibitor of cytochrome P450 3A4 (CYP3A4), the enzyme primarily responsible for the metabolism of carbamazepine. Inhibition of this enzyme reduces the clearance of carbamazepine, leading to increased plasma concentrations.

Elevated carbamazepine levels can cause dose-related toxicity, including dizziness, ataxia, nystagmus, diplopia, nausea, vomiting, and confusion. In severe cases, toxicity may progress to seizures or coma. The onset of interaction is usually within 2 to 3 days of starting erythromycin.

Avoid co-prescription if possible. If combination is necessary, consider using an alternative macrolide such as azithromycin which has less effect on CYP3A4. If erythromycin must be used, monitor carbamazepine plasma levels closely (e.g., every 2 to 3 days initially) and adjust the carbamazepine dose accordingly. Monitor the patient for signs of carbamazepine toxicity.

The interaction is well established in clinical practice and supported by multiple case reports and pharmacokinetic studies. It is listed in major drug interaction compendia.